High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

Epithelial ovarian cancer (EOC) is one of the cancers most influenced by hereditary factors.
A fourth to a fifth of unselected EOC patients carry pathogenic variants (PVs) in a number of …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

The Cancer Genome Atlas (TCGA) is a public funded project that aims to catalogue and
discover major cancer-causing genomic alterations to create a comprehensive “atlas” of …

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …

Overtreatment with cisplatin-based chemotherapy is a major issue in the management of
muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for …

Abstract The Cancer Genome Atlas (TCGA) has used the latest sequencing and analysis
methods to identify somatic variants across thousands of tumours. Here we present data and …

Large-scale genomic studies have shown that half of epithelial ovarian cancers (EOCs)
have alterations in genes regulating homologous recombination (HR) repair. Loss of HR …

Recent studies have revealed extensive genetic diversity both between and within tumours.
This heterogeneity affects key cancer pathways, driving phenotypic variation, and poses a …

Defective DNA repair is a common hallmark of cancer. Homologous recombination is a DNA
repair pathway of clinical interest due to the sensitivity of homologous recombination …